Britain and America have reached a significant commercial pact that will guarantee no duties on British medicine products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the NHS. This move ensures that duties on these vital goods will remain at zero for a duration of 36 months.
This agreement follows earlier statements to hike import taxes on patented drug imports, with increases discussed as high as double the cost.
"This agreement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and introduces long-overdue balance to transatlantic pharmaceutical trade," a statement declared.
Trade Importance
Medicines are one of the the United Kingdom's most significant export categories to the United States, which is by far the largest buyer for leading UK drugmakers.
Export figures show that in the year leading up to last September, the UK exported medicines totaling £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that period.
"This deal safeguards work, boosts funding and paves the way for the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The agreement involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments were more than 20%.
Industry Background
The deal follows a long-running dispute between the sector and the British authorities over drug pricing and approval rates.
The disagreement were heightened by claims that American customers were paying significantly more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
